<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03885778</url>
  </required_header>
  <id_info>
    <org_study_id>ID-BVCL-402</org_study_id>
    <nct_id>NCT03885778</nct_id>
  </id_info>
  <brief_title>A Food Effect Study of Besifovir in Healthy Subjects</brief_title>
  <official_title>An Open Label, Randomized, 2-sequence, 2-period, Single-dose Cross-over Design Clinical Trial to Evaluate the Food Effect on Pharmacokinetics of BESIVO in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the PK characteristics and the effect of food on the PK in healthy volunteers
      who receive Besifovir dipivoxil in fed versus fasted condition
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, 2-sequence, 2-period, single-dose cross-over clinical trial to
      investigate the pharmacokinetics incorporating a comparison of fed/fasted pharmacokinetics of
      Besifovir dipivoxil in healthy volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 13, 2019</start_date>
  <completion_date type="Actual">February 12, 2019</completion_date>
  <primary_completion_date type="Actual">January 28, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration [Cmax] of Besifovir</measure>
    <time_frame>Up to 24 Hours after study drug administration</time_frame>
    <description>The Cmax is the maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve [AUC] of of Besifovir</measure>
    <time_frame>Up to 24 Hours after study drug administration</time_frame>
    <description>Area under the plasma concentration versus time curve for Besifovir</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Besifovir</measure>
    <time_frame>Up to 24 Hours after study drug administration</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to infinite time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the Cmax [Tmax] of Besifovir</measure>
    <time_frame>Up to 24 Hours after study drug administration</time_frame>
    <description>Time to reach the Cmax of Besifovir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life [t1/2]</measure>
    <time_frame>Up to 24 Hours after study drug administration</time_frame>
    <description>apparent terminal half-life of Besifovir</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety of Besifovir: incidence of treatment emergent adverse event [TEAE]'s, abnormalities</measure>
    <time_frame>Up to 14 days after last study drug administration</time_frame>
    <description>Safety of Besifovir administered orally will be assessed by incidence of treatment emergent adverse event [TEAE]'s, abnormalities in vital sign assessments, ECG's, clinical laboratory assessments, and physical exams</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Food Effect</condition>
  <condition>Health Subjects</condition>
  <arm_group>
    <arm_group_label>A-fasted dosing followed by fed dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fasted dosing of Besifovir dipivoxil followed by fed dosing; Dosing in the fasted state followed by fed dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-fed dosing followed by fasted dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fed dosing of Besifovir dipivoxil followed by fasted dosing; Dosing in the fed state followed by fasted dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Besifovir dipivoxil</intervention_name>
    <description>150mg Besifovir dipivoxil, single dose, oral</description>
    <arm_group_label>A-fasted dosing followed by fed dosing</arm_group_label>
    <arm_group_label>B-fed dosing followed by fasted dosing</arm_group_label>
    <other_name>Besivo tab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject who has the ability to comprehend the study objectives, contents and the
             property of the study drug before participating in the trial

          2. Age of 19 to 50 years and Body Mass Index [BMI] of 18.0 to 27.0 kg/m2

          3. Subject with no congenital or chronic disease and no medically symptomatic findings

          4. Subject must be healthy on the basis of vital signs, 12-lead ECG, physical examination
             and laboratory test performed at screening.

        Exclusion Criteria:

          1. Medical history

               -  History of clinically significant of gastrointestinal system, hepatic portal
                  system, cardiovascular system, respiratory system, endocrine system,
                  renal-urinary system, immunologic system, musculoskeletal system, neurological,
                  or psychiatric system, blood tumor, ophthalmology, otolaryngology disorder(as
                  determined by the Investigator).

               -  Prior history of a gastrointestinal disorder that may affect drug absorption,
                  distribution, metabolism and elimination (e.g., Crohn's disease, ulcer or
                  surgery, except for simple appendectomy or hernia surgery)

          2. Clinical tests

               -  Systolic Blood Pressure: lower than 90mmHg or higher than 140mmHg, Diastolic
                  Blood Pressure: lower than 60mmHg or higher than 180mmHg

               -  Repeated measurement of laboratory value outside the reference range that the
                  investigator considers to be of clinical relevance

                    1. Aspartate transaminase [AST] or alanine aminotransferase [ALT] &gt; 1.5 x upper
                       limit of normal range

                    2. Total bilirubin &gt; 1.5 x upper limit of normal range

                    3. estimated glomerular filtration rate [eGFR] &lt; 75mL/min/1.73m2 (using Chronic
                       Kidney Disease Epidemiology Collaboration [CKD-EPI] equations)

                    4. Positive screening on Hepatitis B surface antigen(HBsAg), anti-Hepatitis C
                       virus(HCV), anti-Human immunodeficiency virus(HIV) or Syphilis reagin test

               -  Subjects with clinically significant abnormalities in 12-lead ECG determined by
                  repeated measurement

          3. Allergy, hypersensitivity, and drug abuse

               -  History of significant hypersensitivity to Besifovir, this drug ingredient or
                  other drug (e.g., aspirin, antibiotics)

               -  History of clinically significant allergy/hypersensitivity

               -  A history of drug abuse (especially, central nervous system agents such as
                  sleeping pills, central painkillers, opiates or psychotropic drugs) or the
                  presence of positive reactions to drugs that have abuse potential in urine
                  screenings for drugs(amphetamines, barbiturates, cocaine, opiates, cannabinoids,
                  and benzodiazepines)

          4. The contraindication of comedication drugs and diets

               -  Subject who has taken drugs for drug metabolizing enzyme induction and inhibition
                  within 1 month before the first adminstration

               -  Subject who has taken other ethical the count [ETC] drugs (including prescription
                  of herbal medicine) within the last 14 days, or over the count [OTC] drugs within
                  the last 10 days (as determined by the Investigators)

               -  Subject who has taken abnormal meals (eg. ingestion of grapefruit juice, garlic
                  extract, broccoli, and kale) which can affect to drug absorption, distribution,
                  metabolism, and excretion [ADME] and supplements within 7 days prior to
                  administration of trial medication and during the trial

               -  Subject who has participated in any other bioequivalence study or clinical trial
                  and taken other investigational products within 3 months prior to the first
                  adminstration

          5. Donation and receipt of blood

               -  Subject who had whole blood donation within 2 months prior to administration of
                  trial medication

               -  Subject who had component blood donation or transfusion within 1 months prior to
                  administration of trial medication

          6. Pregnant and contraception

               -  Pregnant, positive of pregnancy test or breast-feeding women

               -  Subjects who do not use medically acceptable contraception during the entire
                  period of the trial

                    1. Use of intrauterine device

                    2. Use of intercourse contraceptive (male or female) and spermicide

                    3. Vasectomy

                    4. Tubectomy, canal ligation and hysterectomy

          7. Other criteria

               -  Use of Xanthine (eg. green tea, coffee, black tea, coke, cocoa, chocolate, energy
                  drink, and etc.) within 3 days prior to administration of trial medication and
                  during the trial

               -  Intake of more than 30g of alcohol per day or who can't abstain from alcohol
                  during the trial

               -  Subjects who can't quit smoking during the trial

               -  Subjects who are considered to be unacceptable in this study under the opinion of
                  the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jong-Lyul GhimK</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

